Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board ("REB") has granted approval for the Royal Columbian Hospital (RCH) to
(Financial Post, 2025-11-05T13:34:58Z)